Skip to main content

ORIGINAL RESEARCH article

Front. Mol. Biosci.
Sec. Molecular Diagnostics and Therapeutics
Volume 11 - 2024 | doi: 10.3389/fmolb.2024.1397281

A Novel Mitochondria-Related Algorithm for Predicting the Survival Outcomes and Drug Sensitivity of Patients with Lung Adenocarcinoma

Provisionally accepted
Xianqiao Wu Xianqiao Wu 1Hang Chen Hang Chen 2Zhen Ge Zhen Ge 1Binyu Luo Binyu Luo 2Hanbo Pan Hanbo Pan 3Yiming Shen Yiming Shen 4Zuorun Xie Zuorun Xie 2Chengwei Zhou Chengwei Zhou 1,5*
  • 1 The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province, China
  • 2 Ningbo Medical Centre Lihuili Hospital, Ningbo, Zhejiang Province, China
  • 3 Shanghai Jiao Tong University, Shanghai, Shanghai Municipality, China
  • 4 Fudan University, Shanghai, Shanghai Municipality, China
  • 5 Ningbo First Hospital, Ningbo, China

The final, formatted version of the article will be published soon.

    Background: Mitochondria have always been considered too be closely related to the occurrence and development of malignant tumors. However, the bioinformatic analysis of mitochondria in lung adenocarcinoma (LUAD) has not been reported yet. Methods: In the present study, we constructed a novel and reliable algorithm, comprising a consensus cluster analysis and risk assessment model, to predict the survival outcomes and tumor immunity for patients with terminal LUAD. Results: Patients with LUAD were classified into three clusters, and patients in cluster 1 exhibited the best survival outcomes. The patients in cluster 3 had the highest expression of PDL1 (encoding programmed cell death 1 ligand 11) and HAVCR2 (encoding Hepatitis A virus cellular receptor 2), and the highest tumor mutation burden (TMB). In the risk assessment model, patients in the low-risk group tended to have a significantly better survival outcome. Furthermore, the risk score combined with stage could act as a reliable independent prognostic indicator for patients with LUAD. The prognostic signature is a novel and effective biomarker to select anti-tumor drugs. Low-risk patients tended to have a higher expression of CTLA4 (encoding cytotoxic T-lymphocyte associated protein 4) and HAVCR2. Moreover, patients in the high-risk group were more sensitive to Cisplatin, Docetaxel, Erlotinib, Gemcitabine, and Paclitaxel, while low-risk patients would probably benefit more from Gefitinib.We constructed a novel and reliable algorithm comprising a consensus cluster analysis and risk assessment model to predict survival outcomes, which functions as a reliable guideline for anti-tumor drug treatment for patients with terminal LUAD.

    Keywords: Mitochondria, tumor immunity, consensus cluster, Risk Assessment Model, Lung Adenocarcinoma

    Received: 08 Mar 2024; Accepted: 26 Jul 2024.

    Copyright: © 2024 Wu, Chen, Ge, Luo, Pan, Shen, Xie and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Chengwei Zhou, Ningbo First Hospital, Ningbo, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.